Welcome to ZMB
Welcome to ZMB
The Center of Medical Biotechnology (ZMB) is an interdisciplinary scientific center of the University of Duisburg-Essen, integrating medical research at the University Hospital and natural sciences at the Campus.
News & Events
RC OHR Seminar Series
The RC OHR Seminar Series explores health in alignment with the One Health concept, linking ecosystem and human health.
First Wednesday of every month, 4:00-5:00 PM CET, online via Zoom
03.06.2026
Prof. Caspar Schwierdrzik, RUB.
01.07.2026
Prof. Helen Blank, RUB.
05.08.2026
Prof. Bernd Sures, UDE.
A lecture series of UDE’s DFG networks in the field of Biomedical Sciences Sex and Gender in the Life Sciences
Perspectives on how research in the life sciences can utilize the analytical potential of the gender dimension and open up new directions.
June 11, 2026 - 4pm online lecture
Sex and Gender in Governance: Transformation, Megatrends, and Public Health*
PD Dr. Ricarda Schmithausen, University Hospital Essen
*in cooperation with the lecture series “Resonance Spaces for Transformation – Opportunities for the Ruhr Region” by the UDE4future action group
ZMB/CRC1430 Seminars
08.09.2026with IMPRS-LM
Helen Walden
Molecular Biosciences, University of Glasgow
13.10.2026with CRC1430
Helle Ulrich, IMB Mainz
Ubiquitin, SUMO and genome maintenance , IMB Mainz
20.10.2026with CRC1430
Hiroaki Suga
Graduate School of Science, The University of Tokyo
24.11.2026with CRC1430
Janine Kirstein
Biochemistry of Aging, Fritz Lipmann Institute
12.01.2027
Chan Cao
Single-Molecule Bioanalysis, University of Geneva
Press Releases 2026
Was Promovierende an der UDE antreibt Victoria Momand
[01.06.2026] Wie fühlt sich Forschung im Alltag an? Victoria Momand gibt Einblicke in ihre Promotion, die von Neugier, Ideen und dem Wunsch geprägt ist, Zusammenhänge auf kleinster Ebene wirklich zu verstehen. Die Biologin zeigt, wie aus Fragen, Geduld und vielen kleinen Schritten Stück für Stück neue Erkenntnisse entstehen und warum Grundlagenforschung so wichtig ist.
Neuer Sonderforschungsbereich an der UDE Rund 12,9 Millionen Euro für Hautkrebsforschung
[15.05.2026] Großer Erfolg für die Universität Duisburg-Essen: Die Deutsche Forschungsgemeinschaft (DFG) richtet den Sonderforschungsbereich 1752 „DYNAMO“ ein. Ab dem 1. Oktober 2026 fördert sie die Forschung zur Verbesserung von Therapien gegen schwarzen Hautkrebs mit 12,9 Millionen Euro. Koordiniert wird der Forschungsverbund von Wissenschaftler:innen der Medizinischen Fakultät der Universität Duisburg-Essen gemeinsam mit Partnerinstitutionen aus Nordrhein-Westfalen.
ZMB Member: Prof. Dr. Alexander Roesch
ZMB Member: Prof. Dr. Kathrin Thedieck
Sonderforschungsbereich verlängert Neue Sicht auf unterschätzte Immunzellen
[15.05.2026] Die Deutsche Forschungsgemeinschaft fördert den Sonderforschungsbereich/Transregio (TRR) 332 „Neutrophile: Entwicklung, Verhalten und Funktion“ für eine zweite Förderperiode mit rund 13 Millionen Euro. Am TRR 332 sind Wissenschaftler:innen der Medizinischen Fakultät der Universität Duisburg-Essen maßgeblich beteiligt.
ZMB Member: Prof. Dr. Jadwiga Jablonska-Koch
ZMB Member: Prof. Dr. Matthias Gunzer
ZMB Member: Prof. Dr. Sven Brandau
ZMB Member: Prof. Dr. Dirk M. Hermann
Neue Humboldt-Stipendiat:innen Internationale Forschung an der UDE
[30.04.2026] Seit diesem Monat forschen fünf Wissenschaftler:innen mit einem Stipendium der Alexander von-Humboldt-Stiftung an der Universität Duisburg-Essen. Fachlich decken ihre Arbeiten verschiedene Bereiche ab, es geht um soziale, biologische, mechanische und rechtstheoretische Fragen. Mit einem Humboldt-Forschungsstipendium für erfahrene Forschende wird unter drei Wissenschaftlerinnen gefördert:
- Die Stipendiatin Dr. Hanieh Jalali (Kharazmi University, Iran) widmet sich Problemen der Entwicklungsbiologie. Ihr Gastgeber ist Prof. Dr. Bernd Giebel vom UDE-Institut für Transfusionsmedizin.
ZMB Member: Prof. Dr. Bernd Giebel
Pint of Science in Duisburg und Essen „Zwischen Bierglas und Weltuntergang“
[24.04.2026]
Drei Abende, drei Locations, viele Perspektiven: Auch in diesem Jahr beteiligen sich Forschende der Universität Duisburg-Essen wieder am internationalen Format „Pint of Science“ und bringen aktuelle Forschung dorthin, wo man sie nicht unbedingt erwartet – in Bars und Kneipen. Vom 18. bis 20. Mai sprechen Wissenschaftler:innen verständlich, nahbar und mitten im Alltag über ihre Themen.
ZMB Member: Prof. Dr. Shirley Knauer
Forschende entdecken neuen Mechanismu Virusinfekte können Allergien verschärfen
[23.03.2026]
Warum verlaufen allergische Reaktionen während einer Virusinfektion oft besonders schwer? Ein Forschungsteam der Medizinischen Fakultät der Universität Duisburg-Essen hat nun einen entscheidenden Mechanismus identifiziert: Bestimmte Immunzellen geraten im antiviralen Alarmzustand außer Kontrolle und können lebensbedrohliche allergische Reaktionen auslösen.
ZMB Member: Prof. Dr. Karl Sebastian Lang
Neu an der UA Ruhr: Alpaslan Tasdogan Tumor-Stoffwechsel im Blick
[17.03.2026]
Wie gelingt es Krebszellen zu überleben und sich im Körper auszubreiten? Dieser Frage widmet sich Prof. Dr. Dr. Alpaslan Tasdogan künftig am Research Center One Health der Universitätsallianz Ruhr. Der Dermato-Onkologe und Immunologe forscht seit vielen Jahren am Universitätsklinikum Essen zum Stoffwechsel von Tumoren. Seit dem 1. März 2026 ist er Professor für „Tumormetabolismus und Mikroenvironment“ im Research Center One Health.
ZMB Member: Prof. Dr. Alpaslan Tasdogan
03.06.2026 - 12:35:00
Autismusrisiko bei Frühgeborenen: Frühere Diagnosen und gezieltere Therapien ermöglichen
ZMB Research Programs
Oncology
The concept of this research program is to understand fundamental processes in tumor biology in order to develop novel molecularly defined and rationally applied cancer treatments.
Participating researchers from biology, experimental and clinical medicine study tumors as “biological systems" and so called “neo-organs”.
A large variety of approaches, experimental systems and methodologies are in place to analyse many aspects of tumor development, growth, progression and tumor cell migration.
Immunology, Infectious Diseases and Transplantation
The immune system responds to various pathogens including viruses and bacteria in different ways to prevent severe disease and persistence in the host. Many pathogens, however, have developed mechanisms to evade immune defence.
The molecular and cellular interactions of pathogens with the immune system are studied within this program.
Molecular and Chemical Cell Biology
Molecular and chemical cell biology is an interdisciplinary research program connecting molecular cell biology and genetics with chemistry and structural biology. Scientists of the participating disciplines collaborate to advance the understanding of basic molecular mechanisms of important biological processes.
The analysis of regulation and deregulation of key pathways is linking basic biology with pathophysiology.
Latest Publications
-
Activated ATF6α is a hepatic tumour driver restricting immunosurveillanceIn: Nature, 2026, in pressDOI (Open Access)
-
Adjuvant Imatinib or Observation in Patients with Gastrointestinal Stromal Tumors with KIT Exon 9 MutationsIn: JAMA Oncology, Vol. 12, 2026, Nr. 4, pp. 407 – 412
-
Advanced Molecular Tweezers Effectively Target Membranes Lacking Choline Headgroups for Broad-Spectrum Antiviral EfficacyIn: Journal of the American Chemical Society: JACS, Vol. 148, 2026, Nr. 3, pp. 3626 – 3637DOI (Open Access)
-
Ancient co-option of LTR retrotransposons as yeast centromeresIn: Nature, 2026, in pressDOI (Open Access)
-
Atomic-Scale Understanding of Selectivity Control in Nitrate Reduction on Cu(100) Under Acidic and Alkaline ConditionsIn: Angewandte Chemie International Edition, 2026, in pressDOI (Open Access)
-
CCL3 is produced by aged neutrophils across cancers and promotes tumor growthIn: Cancer Cell, Vol. 44, 2026, Nr. 3, pp. 624 – 640.e12DOI (Open Access)
-
CUL4A-DDB1-DCAF10 is an N-recognin for N-terminally acetylated Src kinasesIn: Nature Communications, Vol. 17, 2026, Nr. 1, 132DOI (Open Access)
-
Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinomaIn: Nature Communications, Vol. 17, 2026, Nr. 1, 1476DOI (Open Access)
-
Combined transcatheter mitral and tricuspid edge-to-edge repair or tricuspid edge-to-edge repair alone in moderate mitral regurgitation : a propensity-matched analysisIn: European Heart Journal, 2026, in pressDOI (Open Access)
-
Condensins regulate resection-dependent DNA double-strand break repair pathways in replicated chromatinIn: Nucleic Acids Research, Vol. 54, 2026, Nr. 4, gkag076DOI (Open Access)
-
Covalent modification of a glutamic acid inspired by HaloTag technologyIn: Nature Communications, Vol. 17, 2026, Nr. 1, 1257DOI (Open Access)
-
Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal CancerIn: Clinical Cancer Research, Vol. 32, 2026, Nr. 5, pp. 938 – 946DOI (Open Access)
-
Discovery of an Endonuclease G-inhibitory Ku80-peptide protecting against leukemogenic rearrangements at the MLL breakpoint clusterIn: Nature Communications, Vol. 17, 2026, Nr. 1, 3562DOI (Open Access)
-
Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic MelanomaIn: Clinical Cancer Research, Vol. 32, 2026, Nr. 7, pp. 1266 – 1276DOI (Open Access)
-
Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial)In: European Heart Journal, Vol. 47, 2026, Nr. 9, pp. 1034 – 1046DOI (Open Access)
-
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanomaIn: Annals of Oncology, 2026, in pressDOI (Open Access)
-
Interplay of SLC33A1-dependent and -independent Golgi sialic acid O-acetylation in CASD1 catalysisIn: Nature Communications, Vol. 17, 2026, Nr. 1, 3156DOI, Online Full Text (Open Access)
-
M18BP1 valency and a distributed interaction footprint determine epigenetic centromere specification in humansIn: The EMBO Journal, 2026, in pressDOI (Open Access)
-
Molecular anatomy of PLK1 master docking motifsIn: Nature Communications, Vol. 17, 2026, Nr. 1, 4228DOI (Open Access)
-
Molecular requirements for PLK1 activation by T-loop phosphorylationIn: The EMBO Journal, Vol. 45, 2026, Nr. 5, pp. 1496 – 1536DOI (Open Access)
-
Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumorIn: Nature Communications, Vol. 17, 2026, Nr. 1, 3397DOI (Open Access)
-
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaIn: The Journal of Clinical Investigation (JCI), Vol. 136, 2026, Nr. 7, 189152DOI (Open Access)
-
PDS5 proteins control genome architecture by limiting the lifetime of cohesin-NIPBL complexesIn: Molecular Cell, 2026, in pressDOI (Open Access)
-
PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)In: Annals of Oncology, Vol. 37, 2026, Nr. 5, pp. 686 – 700DOI (Open Access)
-
Probing a Reactive Alkyne Center Aligned via a Triphenylmethane Tripod on Au(111) for Electric Field-Induced Chemistry by STM and TERSIn: Small, Vol. 22, 2026, Nr. 7, e09467DOI (Open Access)
-
Sulfated glycosaminoglycans inhibit LCMV entry and modulate antiviral immunity and pathologyIn: EMBO Molecular Medicine, Vol. 18, 2026, Nr. 4, pp. 1235 – 1264DOI (Open Access)
-
Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitorsIn: Nature Communications, Vol. 17, 2026, Nr. 1, 4331DOI (Open Access)
-
The accessory adapters FAF1, FAF2, and UBXN7 accelerate proteasomal degradation by increasing prior p97-mediated substrate unfoldingIn: Science Advances, Vol. 12, 2026, Nr. 10, eaea7381DOI, Online Full Text (Open Access)
-
Thyrotropin-releasing hormone neurons of different hypothalamic nuclei increase energy expenditureIn: Nature Communications, Vol. 17, 2026, Nr. 1, 3499DOI (Open Access)
-
Type I IFN-dependent FcγRIV signaling in murine monocytes promotes lethal anaphylaxis during viral infectionsIn: The Journal of Clinical Investigation (JCI), Vol. 136, 2026, Nr. 4, e192371DOI, Online Full Text (Open Access)
-
Unifying Scaling Relations and Multiple Reaction Mechanisms for Screening Transition Metal-Doped Co3O4 for Oxygen Evolution ReactionIn: Angewandte Chemie International Edition, 2026, e24523 , in pressDOI (Open Access)
-
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010) : A randomised, double-blind, phase 3 studyIn: The Lancet Oncology, Vol. 27, 2026, Nr. 3, pp. 327 – 339DOI (Open Access)